BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
路透社2026/10/09 15:12Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Latest Updates
October 9 - ** Definium Therapeutics (DFTX.O) shares rose 7.4%, to $36.7
** If the rally holds, the stock is on track for its biggest one-day gain since June
** JPMorgan initiated coverage on the stock with an "Overweight" rating and a target price of $84
** The brokerage said Definium’s leading candidate drug DT120 ODT could transform the treatment of neuropsychiatric disorders
** Based on current data, the firm considers DT120 ODT (an LSD oral formulation for major depressive disorder and generalized anxiety disorder) a "de-risked asset"
** The new target price represents 145.7% upside from the latest closing price
** "Although changes in the macro environment may pose potential risks to investment in the sector, we believe the positives for Definium outweigh the negatives," the brokerage said
** A period of "frequent milestone events" is expected going forward, including the planned FDA approval submission in the first half of 2027
** The brokerage expects total DT120 orally disintegrating tablet (ODT) sales to approach $5 billion by 2035
**Including intraday swings, the stock has more than doubled year to date
(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or may not include necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by use of automated translation functionality.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Update: Equities Rise Intraday as Traders Parse Consumer Sentiment Survey
01:37 PM EDT, 10/09/2026 (MT Newswires) -- (Updates with latest market prices and developments.) US benchmark equity indexes were higher intraday as investors evaluated a survey on consumer sentiment. The Dow Jones Industrial Average was up 0.8% at 51,628.8 after midday Friday, while the Nasdaq Composite and the S&P 500 rose 0.6% each to 27,352.4 and 7,809.5, respectively. Barring communication services, all sectors were in the green, led by real estate. US consumer sentiment fell in October as the one- and five-year inflation expectations reached their highest levels since May, preliminary results of a University of Michigan survey showed Friday. "While year-ahead expectations for personal finances and business conditions crept up slightly, buying conditions for durables plummeted amid high prices and borrowing costs," Surveys of Consumers Director Joanne Hsu said. "Frustration over cost-of-living continues to mount, as consumers across the political spectrum believe that the trajectory of the economy has weakened since the beginning of the year." Markets are currently pricing in a nearly 81% probability that the Federal Reserve will keep its benchmark rate steady later this month, with the remaining odds in favor of a second consecutive 25-basis-point hike, as the central bank looks to tame inflation, according to the CME FedWatch tool. West Texas Intermediate crude was down 0.4% at $91.17 a barrel intraday, while Brent lost 0.5% to $103.81. The 10-year US Treasury yield was up 1.5 basis points at 5.25%, while the two-year rate increased 3.9 basis points to 4.8%. In company news, SpaceX (SPCX) shares were up 0.5%. The rocket and satellite company said late Thursday it agreed to acquire a nationwide low-band spectrum portfolio from investment firm Grain Management as it seeks to establish Starlink Mobile as a major US mobile carrier. T-Mobile US (TMUS) shares sank 13% intraday Friday, the worst performer on the S&P 500, followed by AT&T (T) and Verizon Communications (VZ), which fell 10% and 9.8%, respectively.
Ameren declares quarterly dividend of $0.75 a share
Ameren declared a quarterly cash dividend of 75 cents per common share. Dividend payable Dec. 31, 2026. Shareholders of record as of Dec. 8, 2026 will receive the dividend. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ameren Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610091331PR_NEWS_USPR_____CG68019) on October 09, 2026, and is solely responsible for the information contained therein.
McEwen’s $55M Ontario asset sale fuels gold growth plans
US Stock Market Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) debuts on the US stock market; shares fall over 10% after opening
As of press time, the stock has dropped more than 10%, trading at $10.77.
Crypto prices
More
